Safety and efficacy of incobotulinumtoxinA doses up to 800 U in limb spasticity: The TOWER study

OBJECTIVE: To evaluate safety (primary objective) and efficacy of increasing doses (400 U up to 800 U) of incobotulinumtoxinA (Xeomin, Merz Pharmaceuticals GmbH) for patients with limb spasticity. METHODS: In this prospective, single-arm, dose-titration study (NCT01603459), patients (18–80 years) wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Wissel, Jörg, Bensmail, Djamel, Ferreira, Joaquim J., Molteni, Franco, Satkunam, Lalith, Moraleda, Susana, Rekand, Tiina, McGuire, John, Scheschonka, Astrid, Flatau-Baqué, Birgit, Simon, Olivier, Rochford, Edward T.J., Dressler, Dirk, Simpson, David M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5379931/
https://www.ncbi.nlm.nih.gov/pubmed/28283596
http://dx.doi.org/10.1212/WNL.0000000000003789

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5379931/
https://www.ncbi.nlm.nih.gov/pubmed/28283596
http://dx.doi.org/10.1212/WNL.0000000000003789

Ejemplares similares